Phase 2 N=89 2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation
Atrial Fibrillation
Primary: Number of Patients Atrial Fibrillation — 26; 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Head and Neck Cancer Metastatic
Primary: Safety as Measured by Number of Participants With Drug-related Adverse Events — 19; 2 Participants
Phase 2 N=272 A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults
Coronavirus Disease 2019 (COVID-19)
Primary: Adverse Events of Special Interest — 0; 0 Participants
Phase 2 N=155 Safety and Efficacy Study of VIS649 for IgA Nephropathy
Immunoglobulin A Nephropathy · Glomerular Disease · IgAN
Primary: Number of Participants With Adverse Events Graded by Severity — 19; 22; 22; 23 Participants
Phase 2 N=980 Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)
Smoking Cessation
Primary: Percentage of Participants With a 6-month Sustained Abstinence — 23; 45; 18 Participants — p=.779
Phase 2 N=43 A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
Wet Macular Degeneration
Primary: SRD-part: Number of Participants With Ocular Dose Limiting Events (DLEs) — 0; 0; 0; 0 Participants
Phase 2 N=26 Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Castration Resistant Prostatic Cancer · Metastatic Prostate Cancer
Primary: Radiographic Progression-Free Survival Rate (rPFS) at 6 Months — 0.513; 0.63 proportion of participants
Phase 2 N=34 Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
Obesity · Status Post Sleeve Gastrectomy
Primary: Cohen's d (the Standardized Mean Difference) — 2.145 cohen's d
Phase 2 N=198 Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy
Food Allergy
Primary: Percentage (%) of Subjects Who Are Treatment Responders After 12 Months of EPIT Treatment. — 36.7; 49.0; 36.2; 30.2 percent of participants
Phase 2 N=25 Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
Diabetic Macular Edema
Primary: Frequency of Ocular Adverse Events, Systemic Adverse Events, Serious, and Treatment-emergent Non-serious Adverse Events — 10; 8; 3; 5 Participants
Phase 2 N=3 Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Pancreatic Adenocarcinoma · Ovarian Cancer · Biliary Carcinoma
Primary: Safety: Toxicity Symptoms Graded According to CTCAE v4.03. — 61; 139; 411; 7 Number of Events
Phase 2 N=26 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Acute Myelogenous Leukemia · Ovarian Cancer · Colorectal Cancer
Primary: Overall Response Rate (ORR) - Best Overall Response — 0; 0; 1; 0 Participants
Phase 2 N=153 Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
Heart Failure · Chronic Kidney Disease
Primary: Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 — -56.391; -42.085; -58.047; -45.01 Percent change from baseline — p=0.3645
Phase 2 N=6 Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
Autosomal Dominant Hypocalcemia (ADH) · Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Primary: Periods 1, 2 and 3: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 5; 13 Participants
Phase 2 N=217 Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Allergic Rhinitis · Conjunctivitis
Primary: Mean Total Nasal Symptom Score (TNSS) (2 to 6 Hours) During Out-of-season Birch Allergen Environmental Exposure Unit (EEU) Challenge (REGN5713-5714-5715 vs. Placebo) at…